Margo Minissian, PhD, ACNP, from the Cedars-Sinai Heart Institute discusses her session about non-statin therapies for lowering cholesterol, which she will be presenting at Consultant's Cardiometabolic Risk Summit.
Margo Minissian, PhD, ACNP, is a nurse scientist, cardiology nurse practitioner, and clinical lipid specialist at the Barbra Streisand Women's Heart Center at the Cedars-Sinai Smidt Heart Institute in Los Angeles, California.
To register for Consultant's Cardiometabolic Risk Summit, click here.
For more CRS 2018 conference coverage, click here.
ADDITIONAL RESOURCES:
Goff DC, Lloyd-Jones DM, Bennett G, et al; ACCF/AHA Task Force. 2013 ACC/AHA guideline on the assessment of cardiovascular risk [published online November 13, 2013]. Circulation. https://doi.org/10.1161/01.cir.0000437741.48606.98.
ASCVD Risk Estimator Plus. American College of Cardiology. http://tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/estimate/.
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Cardiol Coll. 2014;63(25, part B):2889-2934. doi:10.1016/j.jacc.2013.11.002.
Sabatine MS, Giugliano RP, Keech, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients
with cardiovascular disease. N Engl J Med. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664.
Lloyd-Jones DM, Morris PB, Ballantyne CM, et al; American College of Cardiology Task Force on Expert Consensus Decision Pathways. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease [published online September 5, 2017]. J Am Coll Cardiol. doi:10.1016/j.jacc.2017.07.745.
